#USA #Philadelphia #IFLI #Verismo Therapeutics #SynKIR™-310

Verismo Therapeutics Partners with IFLI

In a significant advancement for the treatment of follicular lymphoma, Verismo Therapeutics has announced its strategic partnership with the Institute for Follicular Lymphoma Innovation (IFLI). This collaboration aims to expedite the development of Verismo's promising KIR-CAR platform technology, specifically focusing on the SynKIR™-310 treatment.

A New Era in Follicular Lymphoma Treatment

Verismo Therapeutics, a clinical-stage biotechnology company, is at the forefront of developing novel therapies for solid tumors and blood cancers. The recent agreement with IFLI marks a pivotal moment in the company’s efforts to address the unmet medical needs of patients suffering from follicular lymphoma (FL).

Through this partnership, Verismo stands to benefit from up to $4.05 million in funding from IFLI, which is dedicated to promoting innovation in FL treatment options. This investment is intended to enhance the development and clinical trials of SynKIR™-310, which aims to treat not only FL but also various non-Hodgkin lymphoma (NHL) subtypes.

IFLI’s expertise will be instrumental in guiding Verismo as it navigates FL-specific clinical considerations. The foundation’s established network will also help expand clinical sites and increase patient enrollment, crucial for advancing the trial process.

Accelerated Development for Patients

Bryan Kim, CEO of Verismo Therapeutics, expressed excitement about the support from IFLI. He stated, "This funding will enable us to expedite the clinical development of our SynKIR™-310 program, which is currently in Phase 1 clinical trials. IFLI’s support will help bring our novel therapies to FL patients more quickly and efficiently."

Verismo is currently conducting an open-label study assessing a single infusion of SynKIR™-310 on patients with relapsed or refractory B-cell NHL, including those with FL. This multicenter study aims to enroll up to 18 participants, measuring the efficacy of the treatment in different dosage levels. With the financial backing from IFLI, Verismo aims to broaden the number of clinical sites focused on FL, facilitating recruitment.

Michel Azoulay, Chief Medical Officer of IFLI, highlighted the significance of this collaboration, stating, "IFLI is excited to support the next wave of transformative cell therapies with Verismo's lead SynKIR™-310. We look forward to seeing positive results from the Phase 1 study that can propel further clinical development for patients not responding to traditional immunotherapy."

Building Collaborative Networks

The Institute for Follicular Lymphoma Innovation is recognized for its commitment to advancing treatments for FL through funding and partnerships. Its support for innovative research, like that at Washington University in St. Louis, demonstrates its dedication to improving comprehension and treatment options for FL.

About Verismo Therapeutics

Verismo Therapeutics is a subsidiary of HLB Innovation and specializes in developing KIR-CAR technology, with SynKIR™-310 being one of its key assets currently in clinical trials. The company aims to address significant challenges associated with advanced solid tumors and B-cell malignancies through its innovative platform.

For further information, visit Verismo Therapeutics and IFLI.

In conclusion, the collaboration between Verismo Therapeutics and IFLI is set to accelerate the development of groundbreaking therapies for follicular lymphoma, paving the way for improved treatment outcomes for patients facing this challenging diagnosis.